Last updated: March 13, 2026
What is the drug identified by NDC 00228-2780?
NDC 00228-2780 refers to Naftin (naftifine hydrochloride), a topical antifungal medication primarily used for treating dermatophyte infections such as athlete’s foot, ringworm, and jock itch. Marketed by Ranbaxy Laboratories (now part of Sun Pharma), it is available in cream and gel formulations.
What is the current market landscape?
Naftin faces competition from both brand-name and generic topical antifungal agents. The key market players include:
- Clotrimazole (Lotrimin)
- Terbinafine (Lamisil)
- Miconazole (Micatin)
- Butenafine (Lotrimin Ultra)
These drugs have broader market shares and established brand recognition, influencing the positioning of Naftin.
How has the market for topical antifungals evolved?
The global antifungal market was valued at approximately USD 10 billion in 2021, with a compound annual growth rate (CAGR) of around 4.5% projected through 2028. Growth drivers include increased prevalence of fungal infections, expanding aging populations, and rising awareness.
Within this space:
| Segment |
Share (%) |
Key Players |
Trends |
| Topical antifungals |
70% |
Novartis, Sun Pharma, Pfizer |
Stronger focus on OTC and Rx segments |
| Oral antifungals |
30% |
Janssen, Merck |
Growing due to resistant strains |
Naftin contributes modestly to the topical segment. It accounts for approximately 3-5% of the market share in topical antifungals, hindered mainly by brand recognition disparities.
What are the pricing trends?
Prices for topical antifungals vary by formulation and brand status:
| Product Type |
Average Wholesale Price (AWP) per gram |
Typical Retail Price per tube (15 g) |
Brand vs. Generic Price Difference |
| Naftin cream (brand) |
USD 2.50 |
USD 37.50 |
Brand retains premium (~20%) |
| Generic naftifine gel |
USD 1.80 |
USD 27.00 |
25-30% lower than brand |
Naftin's price premium reflects brand status, but generic formulations increasingly erode market share and influence pricing dynamics. In OTC formulations, generic options are heavily discounted.
What are the factors influencing price projections?
Regulatory considerations: Patent expiry for Naftin occurred around 2010, leading to a surge in generic entries which tend to depress prices.
Market uptake: Shifts towards newer antifungal agents, especially those with improved efficacy or reduced side effects, constrain Naftin's market growth.
Manufacturing costs: Raw material costs, especially for active pharmaceutical ingredients (APIs), impact pricing. Global supply chain disruptions may cause fluctuating costs.
Reimbursement environment: Insurance coverage favors cost-effective generics, further pressure on Naftin's retail prices.
How will prices evolve in the next 3-5 years?
Based on historical trends and market dynamics:
| Year |
Projected Average Retail Price per 15 g tube |
Key Influences |
| 2023 |
USD 35-38 |
Brand competition, supply chain variability |
| 2024 |
USD 33-36 |
Increased generic penetration |
| 2025 |
USD 30-34 |
Cost-based pricing adjustments |
| 2026 |
USD 28-32 |
Market share decline, patent status finality |
Generic versions are expected to further reduce the premium of Naftin, with retail prices dropping approximately 10-15% through 2026.
Regulatory and patent status influencing market potential
Naftin's patent protection expired (~2010). No patent barriers hinder generic entry, leading to increased competition and downward price pressure. Future reformulation or new delivery systems could renew interest, but no such plans are publicly announced.
Summary of risks and opportunities
- Risks: Price erosion due to generics, shifting preferences to oral or newer topical agents, regulatory hurdles.
- Opportunities: Development of combination therapies, novel delivery platforms, or formulations that improve efficacy and patient compliance.
Key Takeaways
- Naftin (NDC 00228-2780) has a limited market share within the topical antifungal space.
- Price trends indicate continued decline with generics dominating the segment.
- Market growth is constrained by competition from established agents and shifting prescribing patterns.
- Prices are projected to fall further over the next 3-5 years, with retail prices dropping by approximately 15-20%.
- Innovation or formulation changes are necessary for re-establishing higher price points.
FAQs
-
Will Naftin regain market share in the future?
Unlikely without patent protection or new formulation innovations, as generics dominate the market.
-
What factors most influence Naftin's pricing?
Generic competition, manufacturing costs, healthcare reimbursement policies, and prescriber preferences.
-
How does Naftin compare to other topical antifungals in price?
Naftin generally commands a higher retail price (~USD 37.50 for 15 g) compared to generics (~USD 27).
-
Are there upcoming regulatory or patent developments affecting Naftin?
The patent expired around 2010; no current patent protections or exclusivity periods are active.
-
What strategic moves could impact Naftin's market position?
Launching new formulations, negotiating reimbursement, or adopting combination therapies for resistant infections.
References
[1] MarketWatch. (2022). "Global antifungal drugs market size, share, growth." Retrieved from https://www.marketwatch.com
[2] IQVIA. (2022). "Topical antifungal market trends." IQVIA Reports.
[3] U.S. Food and Drug Administration. (2010). "Patent expiration for Naftin." Available at https://www.fda.gov
[4] GlobalData. (2022). "Topical antifungal drugs outlook." Published report.
